Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines.

RNA 52

RNA Genome Genomics DNA 52

pharmaphorum

JANUARY 26, 2023

In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA. Just one mutation can lead to a complete change in protein formation. So, when it comes to proteomics, accuracy is vital.

Genome 129

Genome Genomics Genome Project Genetics 129

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. It has a vibrant community of life-science companies, from global pharma to smaller start-ups.

Drugs 73

Drugs Life Science Gene Therapy Genome 73

Roots Analysis

AUGUST 28, 2022

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. The trend is unlikely to change in the foreseen future. Concluding Remarks.

Genome 52

Genome Genomics RNA Genome Project 52

Drug Discovery World

OCTOBER 6, 2022

Both the binary and quantitative have relied on measurement of protein, DNA, and more recently, RNA. For example, only 37% of patients are found to have an actionable mutation for those undergoing DNA mutation testing using some of the most comprehensive and common testing panels in our industry.

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52